Pharmaceutical company giant Johnson & Johnson has big plans for penetrating the plastic surgery market that until now has been dominated by companies like Allergan and Medicis. J&J has just received U.S. Food and Drug Administration clearance to market Evolence, a new collagen injectable for reducing fine lines and wrinkles, correcting moderate to deep facial wrinkles and folds. Although just approved in the U.S., Evolence has been widely available in Europe since 2004 and in Canada since 2005.
Given the slew of injectable fillers available to consumers, what might make Evolence compelling is that it is made from naturally sourced collagen, unlike Restylane and Juvederm. Evolence uses tendons that are harvested from pigs. If you are not squeamish about having porcine-derived collagen floating under your skin, then Evolence may be for you. The advanced collagen in Evolence has been naturally cross-linked, so it closely follows the three-dimensional structure of your skin’s own collagen. This allows Evolence to integrate well and support your skin’s own existing collagen network by adding structure, strength, and volume for a natural look and feel that last. Evolence is the first collagen injectable proven to last six months, although J&J is seeking approval to claim that Evolence lasts for 12 months. The longevity behind Evolence is achieved through Glymatrix Technology, a manufacturing process that cross-links the collagen with a natural sugar, not synthetic chemicals or substances.
Another bright point of Evolence is that it may cause less post-injection bruising and swelling than Restylane and Juvederm, according to Dr. Kenneth Beer, a West Palm Beach dermatologist.
Only time will tell if Evolence will catch on as an alternative to Restylane and Juvederm.